Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10111018

State groups oppose routine AIDS testing.

D Burda
View original source ↗Export metadata ↓

Abstract

Most state hospital association executives oppose routine testing of hospital workers and patients for AIDS, according to Modern Healthcare's sixth monthly Fax poll of state hospital association presidents. Of the 17 executives who responded to the survey, 13 said their associations oppose routine AIDS testing of hospital workers and 12 oppose routine testing of patients.

Explore related subjects

AIDS SerodiagnosisAcquired Immunodeficiency SyndromeAttitude to HealthData CollectionDiagnostic Tests, RoutineHumansSocieties, HospitalUnited StatesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Burda. 1991-06-24. State groups oppose routine AIDS testing.. https://pubmed.ncbi.nlm.nih.gov/10111018/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Prenatal HIV testing and antiretroviral prophylaxis at an urban hospital--Atlanta, Georgia, 1997-2000.

In 1994, the U.S. Public Health Service (USPHS) recommended the use of zidovudine (ZDV) to reduce perinatal human immunodeficiency virus (HIV) transmission; in 1995, USPHS recommended universal prenatal HIV counseling and voluntary testing. Widespread implementation of these recommendations, together with increased use of antiretroviral therapy (ART) and scheduled cesarean delivery, has resulted in substantial declines in perinatal HIV transmission. However, perinatal HIV transmission continues to occur. To identify missed prevention opportunities, CDC analyzed the incidence of perinatal HIV infection among a cohort of HIV-exposed infants born during 1997-2000 at Grady Memorial Hospital (GMH) in Atlanta, Georgia. This report describes the results of that analysis and underscores the challenges to universal prevention of infant HIV infections. Efforts to reduce perinatal HIV transmission should focus on increasing prenatal care rates, promoting adherence to recommended treatment regimens during pregnancy, and increasing prenatal HIV testing, particularly in areas where missed opportunities for prevention of perinatal HIV transmission persist.

AIDS Serodiagnosis↗
PubMed2004

Does name-based HIV reporting deter high-risk persons from HIV testing? Results from San Francisco.

OBJECTIVE: Name-based HIV reporting has been recommended as a method to track the HIV epidemic but may deter or delay at-risk persons from HIV testing. Previous studies of a deterrent effect of HIV reporting were not conducted in areas with high HIV infection rates and politically active populations. METHODS: In a cross-sectional survey, men who have sex with men (MSM) recruited from gay bars, heterosexuals recruited from the sexually transmitted disease clinic, and injection drug users (IDUs) recruited from street venues were administered a face-to-face anonymous questionnaire. RESULTS: Ninety-four percent of the 118 MSM, 76% of the 99 heterosexuals, and 97% of 105 IDUs surveyed were tested. Six percent of MSM, 9% of heterosexuals, and none of the IDUs correctly identified California's HIV reporting regulations. Of the 75 (25%) participants who thought California had a name-based HIV reporting system, 2 were never tested and 23 had not been tested in the past 12 months. None of those who had never been tested and 2 of those who had not been tested in the past 12 months cited fear of being reported as a reason for not testing recently. CONCLUSION: Fear of reporting is an infrequently cited reason for deterring or delaying testing.

AIDS Serodiagnosis↗
PubMed2004

A simple semi-rapid HIV-1&2 confirmatory immunoassay using magnetic particles.

The Bionor HIV-1&2 Confirmatory Test is a semi-rapid simple immunoassay based on magnetic particles for the confirmation of serological status to human immunodeficiency virus (HIV). The specificity and sensitivity of this assay was evaluated by comparison with the Diagnostic Biotechnology HIV-1 Western blot (WB) 2.2 and the HIV-2/SBL-6669 WB. Bionor's confirmatory test demonstrated 98% specificity when testing sero-negative blood donors and false positive sera in screening tests compared to 81.5 and 71.6%, respectively, using the HIV-1 WB. The sensitivity of this assay for HIV-1 antibody positive sera was 97.9% compared to the WB which was 99.5%. When testing confirmed HIV-2 antibody positive samples, 2/100 scored negative using this confirmatory test similar to other HIV-2 peptide-based line immunoassays available commercially, whilst 8/100 were indeterminate reacting to HIV-2 membrane antigens only. Bionor's confirmatory test detected HIV-1 seropositivity earlier than the WB in longitudinal seroconversion panels and could discriminate between HIV-1 and -2 infection. The number of indeterminate responses was generally reduced significantly using Bionor's confirmatory test compared to the HIV-1 WB. The greater specificity, speed and ease of interpretation of Bionor's confirmatory test renders it an attractive and cost effective alternative to the WB for confirming HIV serological status worldwide.

AIDS Serodiagnosis↗